New Study Reveals Rapid Growth and Potential of Single-Use Bioprocessing Market

The single-use bioprocessing market is divided into five major regions—North America, Europe, Asia Pacific, Latin America (LATAM), and the Middle East and Africa (MEA).

The report "Single use Bioprocessing Market Size, Growth by Product (Media Bags and containers, Bioreactors, Mixers, Assemblies), Application (Cell Culture, Mixing, Storage, Filtration, Purification), End User (Biopharma Companies, CROs, CMOs) - Global Forecast 2026", is projected to reach USD 20.8 billion by 2026, at a CAGR of 20.5%.

The rising demand for biopharmaceuticals and advantages of single-use bioprocessing (such as high energy efficiency, low water usage, less floor space requirement, reduced installation cost, decreased risk of product cross-contamination, and fast implementation) drive the adoption of the single-use bioprocessing market. On the other hand, the high disposable cost and issues related to the transfer of leachable and extractables into the solvent, which can cause contamination, are the major factors restraining the growth of this market.

Emerging markets such as China, India, Japan, and Brazil are expected to present significant growth opportunities for the major stakeholders in this market. The market in the Asia Pacific region is expected to grow at the highest CAGR during the forecast period. The growth in this region can be attributed to the expanding biomanufacturing sector, increasing government support, developing RD infrastructure, and growing outsourcing to this region from North America and Europe.

Download a PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=231651297

Single use Bioprocessing Market - Europe

Around 9.9% of the European gross domestic product (GDP) was spent on healthcare in 2018. (Source: Eurostat). According to PhRMA, medicines deriving from biotech innovations (biopharmaceuticals) account for ~20% of all marketed medicines and represent around 50% of all new medicines in the pipeline. Increasing government support in terms of setting guidelines and rules for the development and pre-marketing, and commercialization approval of biosimilars is a major factor driving the growth of the European biopharmaceuticals market. Owing to this, players in the biopharmaceutical market are expected to increase focus on the RD of innovative biologics, thereby increasing the demand for economic and suitable techniques and equipment for RD. Single-use bioprocessing systems help in reducing initial investments and are suitable for RD; these advantages are driving their higher uptake.

Development and manufacturing costs of biologics are generally higher than those of nonbiologics. Due to the economic downturn in the region, this is expected to be one of the major factors restraining the growth of the biologics market in Europe. However, several European countries have launched new funding initiatives to ensure that the national biotechnology sectors are better positioned.

Single use Bioprocessing Market - GERMANY

Increasing adoption of single-use bioprocessing equipment by biopharma and CDMO companies to drive the market growth

Germany is a mature market with a large pharmaceutical production capacity and high healthcare expenditure. Many companies are expanding their biomanufacturing facilities to fulfill the growing demand for biologics. For instance, in 2021, Richter Helm Biologics GmbH expanded its biological manufacturing facility in Bovenau, Germany.

As bioprocess optimization is the key focus of CDMOs to maintain cost-efficiency, the adoption of single-use bioreactors is increasing as they offer increased flexibility and improved productivity efficiency. For instance, in 2021, Eppendorf expanded production capacity at the Oldenburg in Holstein site in Germany to produce laboratory consumables made of high-quality plastic such as pipette tips and tubes, microtiter plates, and single-use bioreactor vessels. Such developments are expected to drive the growth of the single-use bioprocessing market in Germany.

Single use Bioprocessing Market - UK

Increasing healthcare expenditure is driving the growth of the ventilators market in the country

The growth of the biopharmaceuticals market in the UK is one of the major factors driving the demand for single-use bioprocessing in this region. The key growth drivers for the biopharmaceutical market in the UK are well-established innovation centers for biotechnology (such as the Centre for Process Innovation) and rising government support for an increasing number of biotech clusters in the region. According to the UK BioIndustry Association Report; Life sciences: Catalysing Investment and Growth, in 2018, UK biotech companies raised a funding of USD 2.3 billion (£2.2 billion) of private investment, almost double the amount raised in the previous year and more than 20 times the USD 108 million (£100 million) invested by Innovate UK grant funding in 2017/18 from the previous year. The sector continued this trajectory in the first quarter of 2019, raised USD 197 million (£182 million), almost USD 54 million (£50 million) more than during the same period a year earlier, suggesting the sector could break the fundraising record set in 2018. An increase in funding will boost the biotech industry to adopt advanced technologies for effective biomanufacturing solutions (such as single-use products including media bags, connectors, and bioreactors) to speed up the development of new molecules and increase production efficiency. Thus, an increase in funding for drug development is expected to propel the demand for single-use bioprocessing equipment in the UK.

Single use Bioprocessing Market - FRANCE

Increasing investments in life sciences RD infrastructure development to drive the market growth in France

France has 720 biotech companies and 160 MedTech companies, employing more than 50,000 people. It has the third-largest number of biotech companies in Europe, after Germany and the UK. (Source: BiotechGate; La French Health Tech, 2017).

Increasing private and public funding for biotech research is fueling the growth of the biopharmaceutical market in the country, which in turn drives the demand for single-use technologies, including bioreactors, bags, and containers for efficient bioprocessing.

Single use Bioprocessing Market - REST OF EUROPE

The Rest of Europe (RoE) comprises Italy, Spain, the Netherlands, Switzerland, Sweden, Belgium, Turkey, and the Czech Republic. Among these, Italy and Spain are the major markets for single-use bioreactors and other bioprocessing equipment due to well-established life science research sectors and the pharmaceutical industry in these countries.

The life science research sector in Italy is the third-largest in Europe, after Germany and France. According to an article published in PharmaVOICE (2019), there are 67 life science projects in the discovery phase in Italy. Around half (45%) of the projects are on biotech products [such as monoclonal antibodies (26%), recombinant proteins (10%), and products for cell therapy (3%), gene therapy (4%), and regenerative medicine (2%)]. Similarly, around 700 biotechnology companies are operating in Spain currently. The strong product pipeline and large manufacturing footprint in these countries are factors expected to increase the demand and uptake of single-use bioprocessing products in biomanufacturing processes, thereby driving market growth in this region.

Single use Bioprocessing Market - TOC:

EUROPE

TABLE 136 EUROPE: MARKET, BY COUNTRY, 2017–2020 (USD MILLION)
3.1 GERMANY
- 3.1.1 Increasing adoption of single-use bioprocessing equipment by biopharma and CDMO companies to drive the market growth
  - TABLE 144 GERMANY: MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
  - TABLE 145 GERMANY: SINGLE-USE BIOPROCESSING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
  - TABLE 146 GERMANY: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
  - TABLE 147 GERMANY: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
  - TABLE 148 GERMANY: MARKET, BY END USER, 2017–2020 (USD MILLION)
  - TABLE 149 GERMANY: MARKET, BY END USER, 2021–2026 (USD MILLION)
- 3.2 UK
  - 3.2.1 Rising government support for biotech companies to propel the demand for advanced technologies in the UK
    - TABLE 150 UK: SINGLE USE BIOPROCESSING MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
    - TABLE 151 UK: SINGLE-USE BIOPROCESSING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
    - TABLE 152 UK: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
    - TABLE 153 UK: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
    - TABLE 154 UK: MARKET, BY END USER, 2017–2020 (USD MILLION)
    - TABLE 155 UK: MARKET, BY END USER, 2021–2026 (USD MILLION)
  - 3.3 FRANCE
    - 3.3.1 Increasing investments in life sciences RD infrastructure development to drive the market growth in France
      - TABLE 156 FRANCE: SINGLE-USE BIOPROCESSING MARKET, BY PRODUCT, 2017–2020 (USD MILLION
      - TABLE 157 FRANCE: MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
      - TABLE 158 FRANCE: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
      - TABLE 159 FRANCE: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
      - TABLE 160 FRANCE: MARKET, BY END USER, 2017–2020 (USD MILLION)
      - TABLE 161 FRANCE: MARKET, BY END USER, 2021–2026 (USD MILLION)
    - 3.4 REST OF EUROPE (ROE)
      - TABLE 162 ROE: MARKET, BY PRODUCT, 2017–2020 (USD MILLION)
      - TABLE 163 ROE: SINGLE-USE BIOPROCESSING MARKET, BY PRODUCT, 2021–2026 (USD MILLION)
      - TABLE 164 ROE: MARKET, BY APPLICATION, 2017–2020 (USD MILLION)
      - TABLE 165 ROE: MARKET, BY APPLICATION, 2021–2026 (USD MILLION)
      - TABLE 166 ROE: MARKET, BY END USER, 2017–2020 (USD MILLION)
      - TABLE 167 ROE: MARKET, BY END USER, 2021–2026 (USD MILLION)